- Home
- NBIX vs CTLT Comparison
NBIX vs CTLT Comparison
Compare NBIX & CTLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- CTLT
- Stock Information
- Founded
- NBIX 1992
- CTLT 2007
- Country
- NBIX United States
- CTLT United States
- Employees
- NBIX N/A
- CTLT N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- CTLT Biotechnology: Pharmaceutical Preparations
- Sector
- NBIX Health Care
- CTLT Health Care
- Exchange
- NBIX Nasdaq
- CTLT Nasdaq
- Market Cap
- NBIX 13.1B
- CTLT 11.1B
- IPO Year
- NBIX 1996
- CTLT 2014
- Fundamental
- Price
- NBIX $135.45
- CTLT $63.48
- Analyst Decision
- NBIX Buy
- CTLT Hold
- Analyst Count
- NBIX 23
- CTLT 6
- Target Price
- NBIX $165.00
- CTLT $63.40
- AVG Volume (30 Days)
- NBIX 910.2K
- CTLT 3.3M
- Earning Date
- NBIX 02-05-2025
- CTLT 02-07-2025
- Dividend Yield
- NBIX N/A
- CTLT N/A
- EPS Growth
- NBIX 97.40
- CTLT N/A
- EPS
- NBIX 3.73
- CTLT N/A
- Revenue
- NBIX $2,242,800,000.00
- CTLT $4,422,000,000.00
- Revenue This Year
- NBIX $27.07
- CTLT $8.77
- Revenue Next Year
- NBIX $16.60
- CTLT $8.42
- P/E Ratio
- NBIX $36.33
- CTLT N/A
- Revenue Growth
- NBIX 25.72
- CTLT 4.71
- 52 Week Low
- NBIX $110.95
- CTLT $42.07
- 52 Week High
- NBIX $157.98
- CTLT $63.50
- Technical
- Relative Strength Index (RSI)
- NBIX 68.12
- CTLT 74.48
- Support Level
- NBIX $125.61
- CTLT $63.02
- Resistance Level
- NBIX $130.48
- CTLT $63.25
- Average True Range (ATR)
- NBIX 2.92
- CTLT 0.41
- MACD
- NBIX 0.72
- CTLT 0.17
- Stochastic Oscillator
- NBIX 69.33
- CTLT 99.29
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About CTLT Catalent Inc.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.